Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBIT (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EBIT for 16 consecutive years, with $646000.0 as the latest value for Q4 2025.

  • Quarterly EBIT rose 191.63% to $646000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$11.1 million through Dec 2025, down 116.64% year-over-year, with the annual reading at -$11.1 million for FY2025, 116.64% down from the prior year.
  • EBIT for Q4 2025 was $646000.0 at Anika Therapeutics, up from -$3.2 million in the prior quarter.
  • The five-year high for EBIT was $24.7 million in Q4 2023, with the low at -$12.6 million in Q1 2023.
  • Average EBIT over 5 years is -$451150.0, with a median of -$2.9 million recorded in 2024.
  • The sharpest move saw EBIT skyrocketed 279.8% in 2022, then plummeted 3891.36% in 2025.
  • Over 5 years, EBIT stood at -$9.1 million in 2021, then surged by 279.8% to $16.4 million in 2022, then soared by 50.59% to $24.7 million in 2023, then plummeted by 102.85% to -$705000.0 in 2024, then soared by 191.63% to $646000.0 in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $646000.0, -$3.2 million, and -$4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.